Moderna, Inc. Stocks Forecast

Company Information Moderna, Inc.

Moderna Inc (ticker MRNA, NASDAQ) is a biotechnology company headquartered in Cambridge, Massachusetts, USA.
The main activity of the company is the development of drugs based on “messenger RNA” for the treatment of serious cardiovascular, metabolic and renal diseases, as well as oncology.
The company was founded in 2010, its name was originally spelled “ModeRNA”.
Co-founder and director of Moderna Inc is an American businessman of Armenian origin Noubar Afeyan. The company has 760 employees.

Turnover

In 2019, the company’s revenue amounted to more than $ 60 million.

Image

Moderna Corporation announced that it is entering a new therapeutic area that includes autoimmune and inflammatory diseases, in particular, autoimmune hepatitis. The company also plans to expand its range of innovative vaccines in the near future.

The company gained wide popularity after the announcement of the creation of a vaccine aimed at preventing infection with the COVID-19 coronavirus.

Stocks and quotes

The company’s shares are traded on the NASDAQ exchange and are included in the calculation of the NASDAQ Composite index. There are 368643 thousand shares in circulation, the capitalization of the company is more than $ 8 billion.

Earning potential

In 2019, Moderna shares gained 23.6%, and at the auction on February 24, 2020, Moderna shares – by 27.81%, to $ 23.76. The reason was the news that Moderna sent samples of its mRNA vaccine, tentatively named mRNA-1273, to the National Institutes of Health (NIH). The emergence of a possible means to stop the spread of COVID-19 has become a driver of growth in MRNA quotes.